| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $297,957 | 11 | 100 |
| Jorgensen Nathan D. | Chief Financial Officer | 0 | $0 | 1 | $17,598 | $-17,598 |
| Carter Todd Alfred | Chief Scientific Officer | 0 | $0 | 3 | $40,621 | $-40,621 |
| Swartz Robin | COO & CBO | 0 | $0 | 3 | $55,291 | $-55,291 |
| Sandrock Alfred | President and CEO | 0 | $0 | 4 | $184,446 | $-184,446 |
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed …
Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $297,957 worth of Voyager Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.
| 2026-04-02 | Sale | Sandrock Alfred | President and CEO | 11,511 0.0187% | $3.87 | $44,548 | -14.02% | |
| 2026-02-24 | Sale | Sandrock Alfred | President and CEO | 14,197 0.0256% | $3.79 | $53,807 | -7.41% | |
| 2026-02-24 | Sale | Swartz Robin | COO & CBO | 6,458 0.0116% | $3.77 | $24,347 | -7.41% | |
| 2026-02-24 | Sale | Jorgensen Nathan D. | Chief Financial Officer | 4,668 0.0084% | $3.77 | $17,598 | -7.41% | |
| 2026-02-24 | Sale | Carter Todd Alfred | Chief Scientific Officer | 4,174 0.0075% | $3.76 | $15,694 | -7.41% | |
| 2026-02-18 | Sale | Sandrock Alfred | President and CEO | 11,732 0.0215% | $3.41 | $40,006 | +4.79% | |
| 2026-02-18 | Sale | Swartz Robin | COO & CBO | 3,882 0.0072% | $3.44 | $13,354 | +4.79% | |
| 2026-02-18 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,301 0.0061% | $3.44 | $11,355 | +4.79% | |
| 2026-02-10 | Sale | Sandrock Alfred | President and CEO | 12,192 0.0224% | $3.78 | $46,086 | -5.41% | |
| 2026-02-10 | Sale | Swartz Robin | COO & CBO | 4,569 0.0086% | $3.85 | $17,591 | -5.41% | |
| 2026-02-10 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,525 0.0066% | $3.85 | $13,571 | -5.41% | |
| 2025-10-03 | Sale | Jorgensen Nathan D. | Chief Financial Officer | 7,666 0.0141% | $4.78 | $36,643 | -20.47% | |
| 2025-08-18 | Sale | Ferguson Toby | Chief Medical Officer | 19,000 0.0333% | $3.73 | $70,870 | +2.86% | |
| 2025-04-02 | Sale | Sandrock Alfred | President and CEO | 10,885 0.0198% | $3.43 | $37,336 | +12.61% | |
| 2025-04-02 | Sale | Ferguson Toby | Chief Medical Officer | 10,086 0.0184% | $3.43 | $34,595 | +12.61% | |
| 2025-02-20 | Sale | Sandrock Alfred | President and CEO | 11,702 0.0211% | $4.24 | $49,616 | -11.50% | |
| 2025-02-20 | Sale | Swartz Robin | COO & CBO | 3,894 0.007% | $4.25 | $16,550 | -11.50% | |
| 2025-02-20 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,305 0.006% | $4.26 | $14,079 | -11.50% | |
| 2025-02-11 | Sale | Sandrock Alfred | President & CEO | 16,644 0.0255% | $4.45 | $74,066 | -7.84% | |
| 2025-02-11 | Sale | Swartz Robin | COO & CBO | 6,950 0.0106% | $4.45 | $30,928 | -7.84% |
| NEUROCRINE BIOSCIENCES INC | 10 percent owner | 8575316 13.9169% | $15.69M | 2 | 0 | +7.14% |
| EcoR1 Capital, LLC | director | 3851507 6.2506% | $7.05M | 1 | 3 | +28.87% |
| Sanofi | 2477941 4.0215% | $4.53M | 1 | 0 | <0.0001% | |
| PAUL STEVEN M | President and CEO | 872351 1.4157% | $1.6M | 1 | 0 | <0.0001% |
| GERAGHTY JAMES A | director | 76588 0.1243% | $140,156.04 | 2 | 0 | <0.0001% |
| PIERCE GLENN | 16788 0.0272% | $30,722.04 | 1 | 1 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$130,095 | 43 | 45.19% | $111.24M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 51 | +37.5% | 6M | +19.93% |
| Decreased Positions | 53 | -38.97% | 2M | -7.88% |
| New Positions | 21 | New | 2M | New |
| Sold Out Positions | 9 | Sold Out | 274,626 | Sold Out |
| Total Postitions | 134 | -1.47% | 34M | +12.05% |
| Blackrock, Inc. | $22,597.00 | 10.01% | 5.61M | -124,528 | -2.17% | 2025-09-30 |
| Armistice Capital, Llc | $16,926.00 | 7.5% | 4.2M | -600,000 | -12.5% | 2025-09-30 |
| Vanguard Group Inc | $13,098.00 | 5.8% | 3.25M | +40,147 | +1.25% | 2025-09-30 |
| Millennium Management Llc | $9,240.00 | 4.09% | 2.29M | +1M | +153.85% | 2025-09-30 |
| Vestal Point Capital, Lp | $5,944.00 | 2.63% | 1.48M | 0 | 0% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $5,171.00 | 2.29% | 1.28M | -138,026 | -9.71% | 2025-09-30 |
| Geode Capital Management, Llc | $4,629.00 | 2.05% | 1.15M | +31,765 | +2.84% | 2025-09-30 |
| Erste Asset Management Gmbh | $4,501.00 | 1.99% | 1.12M | 0 | 0% | 2025-09-30 |
| State Street Corp | $3,729.00 | 1.65% | 925,358 | +31,438 | +3.52% | 2025-09-30 |
| Ecor1 Capital, Llc | $2,701.00 | 1.2% | 670,303 | -3M | -82.89% | 2025-09-30 |